A major obstacle to the development of effective treatment of Alzheimer's disease (AD) is successfully delivery of drugs to the brain. We have previously identified a series of benzothiazole phosphonate compounds that block the interaction of amyloid beta peptide (Aβ) with amyloid-beta binding alcohol dehydrogenase (ABAD). A selective and sensitive method for the presence of three new benzothiazole ABAD inhibitors in mouse plasma, brain and artificial cerebrospinal fluid has been developed and validated based on high performance liquid chromatography tandem mass spectrometry. Mass spectra were generated using Micromass Quattro Ultima "triple" quadrupole mass spectrometer equipped with Electrospray ionization interface. Good linearity was obtained over a concentration range of 0.05-2.5 µg/ml. The lowest limit of quantification and detection was 0.05µg/ml. All inter-day accuracies and precisions were within ±15% of the nominal value and ±20%, respectively, at the lower limit of quantitation. The tested compounds were stable at various conditions with recoveries >90.0 % (RSD<10%). The method used for pharmacokinetic studies of compounds in mouse cerebrospinal fluid, plasma, and brain is accurate, precise, and specific with no matrix effect. Pharmacokinetic data showed these compounds penetrate the blood-brain barrier (BBB) yielding 4-50 ng/ml peak brain concentrations and 2 µg/ml peak plasma concentrations from a 10mg/kg dose. These results indicate that our newly synthesized small molecule ABAD inhibitor have good drug properties with the ability to cross the blood brain barrier, which holds a great potential for AD therapy.
INTRODUCTION
Accumulation of the toxic amyloid-beta peptide (Aβ) in the brain is considered to be one of the primary causes for the Alzheimer's disease (AD) pathogenesis. Mitochondria and synaptic dysfunction is an early pathological feature of AD affected brain [1] [2] [3] [4] [5] [6] , with Aβ progressively accumulating in synaptic mitochondria and impairing mitochondrial structure and function including membrane potential, membrane permeability transition pore, respiration, energy metabolism, oxidative stress, mitochondrial dynamics, energy metabolism and calcium homeostasis [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . Aβ binding alcohol dehydrogenase (ABAD) is a mitochondrial enzyme essential for metabolic function within the mitochondria [17] [18] [19] [20] [21] [22] [23] [24] . Since Aβ forms a complex with ABAD, this enzyme has gained considerable interest as a potential target for AD treatment. More specifically, prevention and treatment of AD could perhaps be accomplished through the development of molecules that inhibit the formation of the Aβ-ABAD complex or compounds that block Aβ production.
Recent studies indicate that Aβ toxicity may be linked to the mitochondrial dysfunction present in AD [7, 15, 16, [25] [26] [27] [28] [29] . Through this interaction, Aβ is able to suppress normal ABAD enzymatic activity [30] , while promoting oxidative stress [15, 25] and triggering a signal cascade resulting in apoptosis [15, 25] . Structural studies [15, 26] of this interaction show that introduction of Aβ results in a conformational change in ABAD preventing the binding of NAD + and the loss of ABAD enzymatic activity. Targeted interruption of Aβ-ABAD binding has been shown to suppress Aβ-induced neuronal dysfunction, which suggests that the Aβ-ABAD interaction is a prime target for novel AD treatment [22, 23] . The search has already started for inhibitors of this interaction with the most promising treatments being derived from the class of benzothiazolyl ureas [31] .
Frentizole is a nontoxic antiviral and immunosuppressive benzothiazolyl urea drug [31] , approved by the Food and Drug Administration (FDA) for rheumatoid arthritis and systemic lupus erythematosus. We identified frentizole as a novel inhibitor of the Aβ-ABAD interaction using ELISA-based screening assays for 45 benzothiazole urea compounds [31] . A novel benzothiazole urea with a 30-fold improvement in potency was identified from analysis of the frentizole structure-activity relationship (SAR) [31] . The SAR studies indicated that small electron-withdrawing groups were desirable as substituents on the benzothiazole ring and compounds with a hydroxyl group at the para position of the phenyl ring were particularly potent. In order for these compounds to readily penetrate the bloodbrain barrier (BBB) and enter the target organ [32] [33] [34] , these compounds were converted to benzothiazole phosphonates. Since water solubility is essential, phosphate esters are frequently used as a prodrug strategy. The properties of xenobiotics can be enhanced in several ways by incorporating phosphate groups. Phosphate groups increase water solubility and thereby enable parenteral drug delivery. Phosphate groups can sometimes decrease the adverse effects of drugs and they can also provide significant and sustained delivery of the active drug species to the target organ by in vivo cleavage of the phosphonate carrier/drug linkage to provide a hydrophilic, negatively charged intermediate, which is 'locked' in the brain or other organ [32] [33] [34] [35] [36] . Three potent benzothiazole phosphonate inhibitors of the ABAD-Aβ interaction (A1, A5 and A6) that bind to ABAD were identified using these criteria [37] , they also rescued Aβ-mediated mitochondrial dysfunction [38] . These compounds are therefore potential therapeutic treatments for AD and their pharmacokinetic profile needs to be assessed. Currently, there are no data on the in vivo pharmacokinetic behavior of these compounds. Thus, there is a need to develop reliable analytical methods for evaluating the properties of these inhibitors. Liquid chromatography tandem mass spectrometry (LC-MS/MS) is a proven method for the analysis of chemical compounds and can provide the low detection limits needed for compounds of interest.
The aim of this study is to validate a LC-MS/MS method of analysis with high sensitivity and reliability for the routine analysis of our compounds in mouse plasma and brain. Our objective is to build a pharmacokinetic profile and assess the ability of compounds A1, A5 and A6 to cross the BBB in mice after intravenous administration.
MATERIALS AND METHODS

Chemical and reagents
Benzothiazole amino phosphonate derivatives were synthesized using a three-component reaction of equimolar quantities of aromatic aldehydes, 6-methoxybenzo[d]thiazol-2-amine, and dimethyl phosphate in toluene at reflux temperature in the presence of Mg (ClO 4 ) 2 [37] . In this study, we examined the three compounds that show better biological activity based on binding affinity and effect on mitochondrial function induced by calcium or Aβ [38] . Compounds A1, A5 and A6 were in the form of white powder characterized by melting points of 216 °C, 180 °C, 178 °C and exact masses of 453.0881 ± 0.0004 (n = 5) 0.1 ppm, 395.0819 ± 0.0006 (n = 3) 3.0 ppm and 397.0788 ± 0.0012 (n = 3) 0.3 ppm, respectively. The molecular formula for A1, A5, and A6 are C 19 (Figure 1 ). The purity of the compounds was greater than 99% using HPLC. A sample of 800 nM concentration of each compound gave a chromatogram with S/ N>100 with was no other detectable peak. HPLC grade methanol, ethanol, formic acid, sodium chloride, potassium chloride, calcium chloride, magnesium chloride, HEPES, monosodium phosphate and sodium bicarbonate were purchased from Sigma (USA). A Millipore purification system (Labconco, Kansas City, MO, USA) was used to provide Millipore water.
Instrumentation-A Waters Acquity "classic" UPLC (Waters Corp USA) was used to develop CH 3 CN gradients on a C-18 reverse phase column. Column-effluent was introduced to the electrospray source of a Micromass Quattro Ultima "triple" quadrupole mass spectrometer (Micromass Ltd., Manchester, UK).
Methods
LC method for MS detection-Chromatographic separation was on an ACE C18 column (Mac Mod Analytical, 3µm, Ultra-Inert HPLC Column, 50×2.1mm) protected by a matched ACE guard cartridge. Separation solvents were A: H 2 O (99%), methanol (1%) and formic acid (0.1%) and B: H 2 O (1%), methanol (99%) and formic acid (0.1%) delivered at a flow rate of 400 µl/min. The hydrophobic character of the analytes allows a large injection (50 µl) to chromatofocus on a column at 5% B. After 0.2 min, separation was with a linear gradient of 11% B/min for 4 min. Column wash was to 80% B for 2 min and re-equilibration at 5% B for 1.5 min for a total run-time of 8 min. The first 2 min of chromatographic effluent was diverted to waste.
Mass spectrometry parameters-The mass spectrometer was run in positive ion mode using the electrospray ionization (ESI) source. The source block was 100°C and desolvation gas temperature 300°C. Argon collision gas pressure on a line to the cell was 1E-3 mbar. Quadrupoles 1 and 3 were set to 0.9 amu FWHH. Collision energy and cone voltage settings were optimized for each compound. The data were processed using MassLynx 4.1/ QuanLynx and Graphpad Prism 5. Fragmentation patterns of compounds A1, A5, and A6,
thiazol-2-yl) methanimine were determined by infusing an aqueous/ methanol solution introduce with a T fitting into 30% solvent B from the UPLC for source optimization. The most abundant transitions were chosen for all the three compounds ( Fig.  1) .
Preparation of calibration standards for recovery and quality controls-Stock solutions of A1, A5 & A6 and internal standards (IS) of 1mM in methanol were used to create calibration standards. Fifty microliters of IS (1µg/ml) plus 50 µl of calibration standard were diluted with 100 µl of water for a curve of nominal concentrations 0.05 to 2.5 µg/ml to be injected onto the LC column. Quality control samples were prepared at nominal concentrations of low (0.05 µg/ml), medium (0.875 µg/ml), and high (2.5 µg/ml).
Preparation of calibration standards in matrices and quality controls samples -Calibration standards were prepared by spiking into 50 µl of blank plasma, brain or artificial cerebrospinal fluid (ACSF) to yield final concentrations of 0.05 to 2.5 µg/ml. Quality control (QC) samples were prepared in the same manner at concentrations of 0.05, 0.875 and 2.5 µg/ml for the low, medium and high level.
Sample preparation
ACSF Sample preparation:
Due to the modest volume of CSF available from a mouse i.e., approximately 5 µl per mouse, we have selected an ACSF for development and calibration. The ACSF consists of 126 mM NaCl, 2.5 mM KCl, 20 mM HEPES, 1.2 mM NaH 2 PO 4 , 25 mM NaHCO 3 , 2.4 mM CaCl 2 , and 1.2 mM MgCl 2 at pH 7. Calibration points were 50µl of IS (1µg/ml), 50µl of calibration standard and the mixture then diluted with 100µl of ACSF, yielding final concentrations of IS (0.5 µg/ml) & standard sample (0.05-2.5 µg/ml) such that 50% organic and 50% ACSF solution were injected onto the LC.
Plasma Sample preparation:
Mouse plasma samples, 50 µl, were transferred to a 1.5 ml centrifuge tube and then 50 µL of IS (4 µg/ml) and 50µL of calibration standard sample were vortexed for 30 s. Acetonitrile (0.1ml) was added to precipitate the proteins. After being vortexed for 3min, the sample was centrifuged for 10min at 13000 rpm. Supernatant (50 µl) was diluted with 50 µl water and injected onto the column.
Brain Sample preparation: Brain tissue 100 mg was weighed and placed in a centrifuge tube. Methanol (100 µl) was added and homogenized for 1min before adding 100 µl IS (6 µg/ml) to the homogenized mixture. The sample was vortexed for 30 s before centrifuging for 10 min at 13000 rpm. Then supernatant liquid was diluted 50% with water and injected.
Method validation: The developed method was validated in terms of selectivity, linearity, lower limits of quantification (LLOQ), accuracy, precision, recovery, stability and matrix effects according to the FDA guidelines [39] .
Accuracy and precision: Intra-day accuracy was calculated by using replicates (n = 5) of A1, A5 and A6 at three concentrations 0.05, 0.875 and 2.5 µg/ml of the spiked matrices during a single analytical session. The inter-day precision was also assessed by using replicates (n = 5) of three concentrations made on three separate days.
Stability:
The stability of compounds A1, A5 and A6 was evaluated in ACSF, plasma and brain matrices under various temperature and storage conditions. Stability at room temperature was examined by analyzing samples at 25°C for 2 and 4 h and stability at −80°C was checked for one month. Samples were analyzed after three freeze-thaw cycles (−80°C to 25°C). Stability studies were performed at three concentrations.
Matrix effects assessment:
Matrix effects were assessed with a post column infusion method. A pump infused each analyte at low concentration at a constant rate into a T fitting post column. The spectrometer was set to SRM mode for that target. Sample preparations, without analyte, were resolved on the LC column.
Extraction Recovery: The extraction recovery of each analysis was determined at the three concentrations low, mid and high (0.05, 0.875, and 2.5 µg/ml) using the non-dosed ACSF, plasma and brain samples. To determine the recovery, signals of spiked extracts from the blank ACSF, brain and plasma were compared with that of injection of pure standards in mobile phase. IS recovery was determined for a single concentration of 0.5 µg/ml.
Linearity and LLOQ:
A calibration curve was prepared from a plot of the peak area ratio (y) of each analyte to IS against plasma concentration (x) using weighted (1/x) least squares regression analysis.
Application to pharmacokinetic study and data analysis: This study was performed in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. Animal studies were approved by the Animal Care and Use Committee of University of Kansas in accordance with the National Institutes of Health guidelines for animal care. Using the validated LC-MS/MS method, blood and brain levels A1, A5 and A6 were measured in male and female C57BL6 mice (8-week-old, weighing approximately 25-30 g). The mice were housed in a room with controlled temperature (23 ± 3°C) and moisture level (55 ± 15% relative humidity) and exposed to a controlled 12 h light/12 h dark cycle. They were allowed to access to food and water ad libitum. Mice were fasted for 6h with free access to water prior to the pharmacokinetic study. To determine the time course of compounds A1, A5 and A6 action in the brain, we investigated the plasma pharmacokinetics and BBB penetration capability of the inhibitors. In these experiments, A1, A5 and A6 were administered to mice by intravenous injection at a dosage of 10 mg/kg. Blood and brain samples were collected from mouse at each time point (2, 5, 10, 30, 60, 120, 240, 360, 720, 1440 and 2880min), a total of 11 time points. For plasma measurements, blood (approximately 500-800 µl) was collected via cardiac-puncture into tubes containing sodium heparin anti-coagulant. Plasma was separated via centrifugation (4°C, 3500 rpm, 10 min) and stored in −80°C freezer. Qualitative confirmations of these compounds in CSF; samples were collected at 2 time points (240 and 1440min) from five animals at each time points. At the time of measurement, frozen plasma samples were thawed at room temperature and vortexed thoroughly. The following quantities were estimates using non-compartmental calculations performed with WinNonlin™ 5.2 (Pharsight, Sunyvale, CA): 1) The area under the plasma concentrationtime curve during the period of observation (AUC 0-t ); 2) The area under the plasma concentration-time curve from zero to infinity (AUC 0-∞ ); 3) The maximum plasma concentration (C max ); 4) The time to reach C max (T max ); and 5) The half-life (t 1/2 ).
RESULTS
Method development
During the development of a detection method for analytes A1, A5 and A6, multiple solvents were tested to find the optimal mobile phase. Compounds A1, A5 and A6 dissolved partially in water, but dissolved readily in methanol or acetonitrile. Acetonitrile was selected for better peak shape and compatibility with serum/brain protein precipitation. A5 and A6 were chosen as IS of A6, A1 and A5, respectively, because of their structural similarity. Selected reaction monitoring (SRM) acquisitions were used for sensitivity and extended dynamic range. The cone voltage and collision energy were optimized for A1, A5 and A6 and the IS by continuously infusing a mixture of the two. The optimum cone voltage was 30 V.
Matrix effects-There were no significant differences between the peaks generated by either the analytes extracted from the none-dosed ACSF, brain, and plasma or the analytes injected from water. The post-column infusion of 1 µg/ml A1, A5 or A6 showed no change of signal greater than 10% from sample matrix in their elution time windows.
Method validation
Selectivity-Selectivity was evaluated by analyzing non-dosed ACSF, brain, and plasma from three different mice. Individual samples were analyzed using LC-MS/MS conditions to prevent interference with A1, A5 and A6 as well as IS. No other endogenous peaks could be detected other than our analyte peaks, (Figure 2 & 3) .
Linearity & LLOQ-The calibration curves were constructed by plotting the IS peak area ratio for analytes A1, A5 and A6 against the concentrations of the IS (A5 and A6). Each of the three calibrations curves (one for each matrix) were characterized by a linear segment and prepared in concentrations spanning 0.05-2.5 µg/ml. The regression equation for ACSF, plasma and brain for A1, A5 and A6 are listed in the (Table 1) . Our LLOQ was 0.05 µg/ml from which a precision of < 10% RSD was observed.
Accuracy and precision-The intra-day and inter-day accuracy and precision values were determined after analyzing five replicates at three separate concentration levels ( Table  2) . Intra-day accuracy for all three analytes ranged from 91.5% to 112.5% and contained a RSD range of 0.36% to 9.24%. All samples analyzed maintained a variability of <10% (RSD) ( Table 2) . These results support the accuracy, reliability and reproducibility of our method.
Stability-The stability of ABAD compounds were determined under different temperature and storage conditions (Table 3) . A1, A5 and A6 standards were dissolved in methanol and were subjected short-term exposure at 25°C for 2 and 4 h long-term storage conditions were assessed at −20°C for twenty days. The displayed variability across all samples was less than 10% (RSD).
Pharmacokinetic profile of compound A1, A5 and A6-The LC-MS/MS method described above was used for the determination of A1, A5 and A6 in plasma, brain, and CSF for pharmacokinetic study. This is the first time such a method has been developed and utilized for this purpose. Figure 4 illustrates the plasma concentration-time profiles of A1, A5 and A6 with intravenous administration. Based on the initial concentration data, the pharmacokinetic parameters including the area under the plasma concentration-time curve during the period of observation (AUC 0-t ), the area under the plasma concentration-time curve from zero to infinity (AUC 0-∞) the maximum plasma concentration (C max ), the time to reach C max (T max ) and the half-life (t 1/2 ) are shown in Table 4 .
DISCUSSION
Molecular AD treatments need to cross the BBB to be effective. This restrictive membrane preserves the brain environment due to tight junctions between endothelial cells and transport mechanisms. It limits the access and distribution of molecules into the brain. Successful central nervous system (CNS) drugs have to cross the BBB, and this is often a limiting factor. Earlier studies in our laboratory have provided a series of small molecule benzothiazole phosphonates derivatives with low micromolar IC 50 values against human ABAD [38] . These in vitro studies led us to choose the small molecule ABAD inhibitors (A1, A5 and A6) from this series for mouse pharmacokinetic studies. A detailed pharmacokinetics study of these new drugs candidates was therefore needed, and we have developed a new analytical LC-MS/MS approach to study the pharmacokinetic profiles of A1, A5 and A6 and describe it herein for mice plasma and brain samples after intravenous administration. The conditions for analysis and sample preparation were optimized, and the method was validated in terms of selectivity, sensitivity, accuracy, precision, and extraction recovery.
Pharmacokinetics provide new insights into the important role for understanding metabolism of drug action and is one of the most important techniques for elucidating the clinical efficacy or/and explaining and predicting a variety of events related to the efficacy [40] [41] [42] [43] . The present study reveals a plasma and brain concentration-time curve for the three compounds. The detectable levels in brain suggested that the small molecule ABAD inhibitors (A1, A5 and A6) are able to cross the BBB.
CONCLUSION
To the best of our knowledge, this is the first report to validate a new LC-MS/MS analytical procedure for evaluating the pharmacokinetics of small molecule ABAD inhibitors (A1, A5 and A6) in mice. Our results clearly demonstrate that the LC-MS/MS method has excellent and satisfactory selectivity, sensitivity, linearity, precision, accuracy, and recovery. The separation of each analyte was conducted using a C-18 column along a methanol gradient. Each analyte was detected using tandem mass spectrometry-positive ion mode; followed by SRM experiments to observe the ions of each compound. Linearity was obtained using a concentration range of 0.05-2.5 µg/ml. The LLOQ and LLOD was 0.05 µg/ml. This specific and selective LC-MS/MS method was applied to a pharmacokinetic study after intravenous administration of A1, A5 and A6 and can be used in future pharmacokinetic studies. The compounds also efficiently cross the BBB and could therefore be effective AD drugs. The present in vivo pharmacokinetic studies of A1, A5 and A6 in mice provide valuable information for the systematic assessment and development of suitable dosage forms and clinical references concerning rational administration.
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